- Home
- REFI vs EYPT Comparison
REFI vs EYPT Comparison
Compare REFI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | EYPT |
|---|---|---|
| Founded | 2021 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 273.3M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | REFI | EYPT |
|---|---|---|
| Price | $9.35 | $0.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $15.13 | ★ $25.91 |
| AVG Volume (30 Days) | 190.0K | ★ 13.4M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | ★ 20.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $48,857,628.00 | $7,539,000.00 |
| Revenue This Year | $0.76 | N/A |
| Revenue Next Year | $7.89 | $967.16 |
| P/E Ratio | $16.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.76 | $0.39 |
| 52 Week High | $13.49 | $19.11 |
Technical Indicators
Market Signals| Indicator | REFI | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 15.29 |
| Support Level | N/A | N/A |
| Resistance Level | $10.97 | $3.57 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 50.00 | 0.70 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.